Ceftaroline is a novel cephalosporin active against MRSA. Its mechanism of anti-MRSA activity involves:

• A Inhibiting the mecA gene transcription via a novel efflux pump blockade
• B Synergistic action with vancomycin against the cell wall D-Ala-D-Lac terminus
• C Irreversible binding to PBP2a with higher affinity than other beta-lactams ✓
• D Forming a dual inhibitor complex with both PBP2a and beta-lactamase

Explanation

Ceftaroline has a unique R1 side chain that allows it to bind PBP2a (encoded by mecA), the low-affinity PBP responsible for MRSA resistance, with sufficient affinity to inhibit cell wall cross-linking and produce bactericidal activity. Conventional beta-lactams have negligible affinity for PBP2a. Ceftaroline does not affect mecA gene expression, does not form dual complexes with beta-lactamases, and its mechanism is independent of vancomycin's action on D-Ala-D-Lac termini (which is relevant to vancomycin-resistant enterococci).

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.